Products for Research Use Only

Indazole

CAT: 0804-HY-40294-01Size: 1 gDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-40294-01Size:1 g
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Indazole, also called isoindazole, a heterocyclic aromatic organic compound. Its derivatives display a broad variety of biological activities including anti-inflammatory, antibacterial, anti-HIV, antiarrhythmic, antifungal and antitumour properties. Indazole and its derivatives can be used for research of cancer, neurological disorders, cardiovascular diseases, gastrointestinal diseases[1][2][3][4][5].
CAS Number
271-44-3
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
GSK-3; LRRK2; Monoamine Oxidase
Type
Reference compound
Related Pathways
Autophagy; Neuronal Signaling; PI3K/Akt/mTOR; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Neurological Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/indazole.html
Concentration
10mM
Purity
99.83
Solubility
DMSO : ≥ 100 mg/mL
Smiles
C12=CC=CC=C1NN=C2
Molecular Formula
C7H6N2
Molecular Weight
118.14
Precautions
H302, H315, H319, H335
References & Citations
[1]Shang C, et al. The Anticancer Activity of Indazole Compounds: A Mini Review. Curr Top Med Chem. 2021;21 (5) :363-376. |[2]Pal D, et al. Importance of Indazole against Neurological Disorders. Curr Top Med Chem. 2022;22 (14) :1136-1151. |[3]Uppulapu SK, et al. Indazole and its Derivatives in Cardiovascular Diseases: Overview, Current Scenario, and Future Perspectives. Curr Top Med Chem. 2022;22 (14) :1177-1188. |[4]Saha S, et al. Indazole Derivatives Effective against Gastrointestinal Diseases. Curr Top Med Chem. 2022;22 (14) :1189-1214. |[5]Qin J, et al. Indazole as a Privileged Scaffold: The Derivatives and their Therapeutic Applications. Anticancer Agents Med Chem. 2021;21 (7) :839-860.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported